For example, among major tumour suppressors, recurrence CDKN2A increased from 25% to 43% and SMAD4 from 14% to 27%, PTEN from 4% to 17% and APC to from 10% to 22% while TP53 showed a predominance of SNV alterations (Fig. 3, Supplementary Data 9). The gene discussed is TP53; the disease is neoplasm.